VanEck Pharmaceutical ETF
PPH
41 hedge funds and large institutions have $55.8M invested in VanEck Pharmaceutical ETF in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 10 closing their positions.
0.59% less ownership
Funds ownership: 31.93% → 31.34% (-0.59%)
8% less capital invested
Capital invested by funds: $60.8M → $55.8M (-$5M)
11% less funds holding
Funds holding: 46 → 41 (-5)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
74% less call options, than puts
Call options by funds: $1.74M | Put options by funds: $6.77M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WWM
Western Wealth Management
Golden,
Colorado
|
+$8.28M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3.87M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.25M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.77M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$16.6M |
| 2 |
Cerity Partners
New York
|
-$1.3M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.18M |
| 4 |
FA
Fortis Advisors
Wayne,
Pennsylvania
|
-$763K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$310K |
PPH Hedge Fund Activity: Q2 2019 in Review
41 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2019, worth a combined $55.8M — down 8.2% from $60.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PPH and 5 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was Western Wealth Management, opening a new position worth an estimated $8.28M. The largest seller was Goldman Sachs, cutting an estimated $16.6M.
- 41 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2019, down from 46 in Q1 2019.
- Funds reported $55.8M of VanEck Pharmaceutical ETF stock for Q2 2019, down 8.2% quarter-over-quarter.
- 5 funds opened new VanEck Pharmaceutical ETF positions in Q2 2019 and 10 closed out, a net change of -5 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2019 was Western Wealth Management, an estimated $8.28M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2019 was Goldman Sachs, an estimated $16.6M sold.
Based on aggregated 13F filings for Q2 2019.